Trial Profile
APIXABAN DRUG UTILIZATION STUDY IN STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Vitamin K antagonists
- Indications Stroke
- Focus Therapeutic Use
- Sponsors Pfizer
- 27 Feb 2018 New trial record